Paraneoplastic cerebellar degeneration with anti-Yo antibody in a patient with HER2/neu overexpressing breast cancer: A case report with a current literature review

Breast Journal

Volumn 14, Issue 4, 2008, Pages 382-384

  Ogita, Shin ^a   Llaguna, Omar H ^a,b   Feldman, Sheldon M ^a   Blum, Ronald ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Anti yo antibody; Breast cancer; Cerebellar degeneration; Her2 neu; Paraneoplastic syndrome

Indexed keywords

ANTIBODY; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG; YO ANTIBODY; AUTOANTIBODY; CDR2 PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; PARANEOPLASTIC NEUROPATHY; PHYSICAL EXAMINATION; PROTEIN EXPRESSION; TREATMENT OUTCOME; BLOOD; BREAST TUMOR; IMMUNOLOGY; METABOLISM; REVIEW;

AUTOANTIBODIES; BREAST NEOPLASMS; FEMALE; HUMANS; NERVE TISSUE PROTEINS; PARANEOPLASTIC CEREBELLAR DEGENERATION; RECEPTOR, ERBB-2;

EID: 54049118506     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2008.00604.x     Document Type: Article

References (14)

1. Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42:1931-7.
2. Hammack JE, Kimmel DW, O'Neill BP, et al. Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin Proc 1990;65:1423-31.
3. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000;55:713-5.
4. Candler PM, Hart PE, Barnett M, et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004;75:1411-5.
5. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;6:1409-18.
6. Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990;322:1844-51.
7. Okano HJ, Park WY, Corradi JP, et al. The cytoplasmic Pur-kinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev 1999;13:2087-97.
8. Graus F, Illa I, Agusti M, et al. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 1991;106:82-7.
9. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000;68:479-82.
10. Rupasinghe J, Butler E. Progressive ataxic gait disorder. J Clin Neurosci. 2007;14:153-7.
11. Sancho MI, Lopez MR, Martinez LC, et al. Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression. Clin Breast Cancer. 2006;7:79-80.
12. Dalmau J, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med 2007;356:612-20.
13. Frings M, Antoch G, Knorn P, et al. Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol 2005;252:197-201.
14. Dorn C, Knobloch C, Kupka M et al. Paraneoplastic neurological syndrome: patient with anti-Yo antibody and breast cancer: a case report. Arch Gynecol Obstet. 2003;269:62-5. Epub 2002 Nov 7.